IP Library Granted Patent US 9,289,441
Granted Patent B2
US 9,289,441 · App. 14/639,013 · Granted Mar 22, 2016

Osteoclast inhibitors such as zoledronic acid for low back pain treatment

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,289,441
App. No.
14/639,013
Granted
Mar 22, 2016
Kind
B2
Abstract

Methods for the safe administration of imidazole or imidazolium compounds, and conditions that may be treated by these methods, are described herein.

Claims (12)

1. A method of treating Modic changes type I, comprising administering an osteoclast inhibitor to a mammal in need thereof, wherein the mammal experiences pain relief three months after the osteoclast inhibitor is administered; and

wherein the osteoclast inhibitor is risedronic acid, cimadronic acid, or etidronic acid.

2. The method of claim 1 , wherein the osteoclast inhibitor is administered orally.

3. The method of claim 1 , wherein the Modic change is located at C1/2, C2/3, C3/4, C4/5, C5/6, or C6/7.

4. The method of claim 1 , wherein the Modic change is located at C7/T1, T1/2, T2/3, T3/4, T4/5, T5/6, T6/7, T7/8, T8/9, T9/10, T10/11, or T11/12.

5. The method of claim 1 , wherein the Modic change is located at T12/L1, L1/2, L2/3, L3/4, L4/5, or L5/S1.

6. The method of claim 1 , wherein the osteoclast inhibitor is administered weekly.

7. The method of claim 1 , wherein the osteoclast inhibitor is administered weekly for 1 or 2 months.

8. The method of claim 1 , wherein the osteoclast inhibitor is administered once a month or less frequently.

9. The method of claim 1 , wherein the osteoclast inhibitor is administered 2 to 5 times in a month.

10. The method of claim 1 , wherein the osteoclast inhibitor is administered daily.

11. The method of claim 10 , wherein the osteoclast inhibitor is orally administered for 5 to 10 consecutive days.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2015
From: TABUTEAU, HERRIOT
To: ANTECIP BIOVENTURES II LLC
Reel/Frame 035096/0543 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2015
From: KARPPINEN, JARO I.
To: AXSOME THERAPEUTICS, INC.
Reel/Frame 035096/0749 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2015
From: AXSOME THERAPEUTICS, INC.
To: ANTECIP BIOVENTURES II LLC
Reel/Frame 035096/0885 →